Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genetic Services Laboratory, |
RCV000192736 | SCV000248765 | uncertain significance | not specified | 2014-11-03 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000706064 | SCV000835095 | uncertain significance | RYR1-related disorder | 2022-10-18 | criteria provided, single submitter | clinical testing | This sequence change affects codon 4882 of the RYR1 mRNA. It is a 'silent' change, meaning that it does not change the encoded amino acid sequence of the RYR1 protein. This variant also falls at the last nucleotide of exon 101, which is part of the consensus splice site for this exon. This variant is present in population databases (rs536148030, gnomAD 0.1%). This variant has not been reported in the literature in individuals affected with RYR1-related conditions. ClinVar contains an entry for this variant (Variation ID: 212095). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV002485290 | SCV002790437 | uncertain significance | Central core myopathy; Malignant hyperthermia, susceptibility to, 1; Congenital multicore myopathy with external ophthalmoplegia; Congenital myopathy with fiber type disproportion; King Denborough syndrome | 2022-04-06 | criteria provided, single submitter | clinical testing | |
All of Us Research Program, |
RCV003996907 | SCV004817298 | likely benign | Malignant hyperthermia, susceptibility to, 1 | 2023-12-13 | criteria provided, single submitter | clinical testing |